Is Now The Time To Look At Buying Progyny, Inc. (NASDAQ:PGNY)?
The Latest Analyst Ratings For Progyny
Progyny Cut to Neutral From Overweight by JP Morgan
Progyny Price Target Cut to $17.00/Share From $22.00 by JP Morgan
J.P. Morgan Downgrades Progyny(PGNY.US) to Hold Rating, Announces Target Price $17
Progyny's Short-Term Challenges and Long-Term Promise: A Hold Rating Amidst Market Pressures
Express News | Progyny Inc : JP Morgan Cuts to Neutral From Overweight
Meridian Hedged Equity Fund Decided to Sell Its Holdings in Progyny (PGNY). Here's Why
Progyny (NASDAQ:PGNY) Earnings and Shareholder Returns Have Been Trending Downwards for the Last Three Years, but the Stock Rallies 11% This Past Week
Here's Why Progyny (PGNY) Was Under Pressure in Q3
Health Care Roundup: Market Talk
Progyny Is Maintained at Overweight by Barclays
Progyny, Inc. to Present at Jefferies London Healthcare Conference
A Quick Look at Today's Ratings for Progyny(PGNY.US), With a Forecast Between $17 to $22
Progyny Price Target Lowered to $21 From $22 at BofA
Progyny CEO Says Election Didn't Contribute to Weak 3Q -- Market Talk
Progyny Isn't Sure Why Its Members Aren't Pursuing More Fertility Care -- Market Talk
Jefferies Adjusts Progyny Price Target to $19 From $24, Maintains Buy Rating
These Analysts Slash Their Forecasts On Progyny Following Q3 Results
Sector Update: Health Care Stocks Rise Premarket Wednesday